Zacks Investment Research upgraded shares of Xtant Medical Holdings Inc (NASDAQ:XTNT) from a sell rating to a hold rating in a research report report published on Wednesday morning.
According to Zacks, “Xtant Medical Holdings, Inc. develops, manufactures and markets biologics products. The Company’s product used in an applications which includes enhancing fusion in spine surgery, relief of back pain, promotion of bone growth in foot and ankle surgery, promotion of cranial healing following neurosurgery and subchondral repair in knee and other joint surgeries. Xtant Medical Holdings, Inc., formerly known as Bacterin International Holdings, Inc., is based in Belgrade, United States. “
Separately, HC Wainwright reaffirmed a buy rating on shares of Xtant Medical Holdings in a research report on Thursday, August 4th.
Shares of Xtant Medical Holdings (NASDAQ:XTNT) opened at 0.79 on Wednesday. The firm’s market capitalization is $9.63 million. The company has a 50-day moving average price of $1.10 and a 200 day moving average price of $1.70. Xtant Medical Holdings has a 12-month low of $0.72 and a 12-month high of $3.75.
About Xtant Medical Holdings
Xtant Medical Holdings, Inc, formerly Bacterin International Holdings, Inc, develops, manufactures and markets regenerative medicine products and medical devices for domestic and international markets. The Company operates through the development, manufacture and marketing of regenerative medical products and devices segment.